Loading…
Loading…
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MUC and 80,000+ other tickers.
See exactly how MUC's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MUC and 80,000+ other tickers.
The BlackRock MuniHoldings California Quality Fund, Inc. (MUC) is a closed-end investment vehicle initially brought to market by BlackRock, Inc. Its day-to-day management falls under the purview of BlackRock Advisors, LLC. This fund primarily allocates capital within the fixed-income sector, focusing predominantly on a portfolio of high-quality, long-term municipal debt instruments. A significant benefit of these holdings is that the interest they generate is exempt from both federal and California state income taxes. MUC was established in 1997 and operates from its domicile in the United States.
NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ARR-002, a potential first-in-class MUC16/NaPi2b targeting tetravalent antibody-drug conjugate (ADC) with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors.
BlackRock MuniHoldings California Quality Fund offers targeted California muni exposure, appealing primarily to state residents seeking tax-advantaged income. MUC has recently outperformed not only its muni peers but also the S&P 500, an atypical achievement for municipal bond funds. The fund's strong performance supports a bullish outlook, with its risk-adjusted returns standing out in the current market environment.
MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets MUC16 is highly and stably expressed in the most aggressive and most common subtypes of endometrial cancer Findings support Whitehawk's development of MUC16-directed ADC, HWK-016, currently being explored in Phase 1 for advanced ovarian and endometrial cancers MORRISTOWN, N.J., April 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today presented three posters from a real-world analysis supporting the therapeutic potential of targeting mucin 16 (MUC16) with a next-generation ADC for the treatment of ovarian and endometrial cancers at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on Women's Cancer, being held April 10-13, 2026, in San Juan, Puerto Rico.
Allspring Global Investments Holdings LLC increased its position in shares of BlackRock MuniHoldings California Quality Fund, Inc. (NYSE: MUC) by 17.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 593,053 shares of the company's stock after
NEWTOWN SQUARE, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced two poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California April 17-22.